Background and Aim COVID‐19 is a new pandemic disease recognized by the World Health Organization. It mainly affects the respiratory system, but it can also affect other systems. The gastrointestinal system has been found to be affected in many patients. This study investigated the COVID‐19‐related gastrointestinal manifestations and the effect of gastrointestinal involvement on the course and outcome of the disease. Methods This was a retrospective descriptive study conducted on 140 COVID‐19 polymerase chain reaction‐positive symptomatic individuals admitted to Al‐Shafa Hospital – Medical City Complex in Baghdad, Iraq during the period 2 March 2020 to 12 May 2020. Demographic data and clinical presentation and laboratory data were extracted from the case sheets of the patients and were also obtained from direct communication with the patients, their families, and medical staff. Results Gastrointestinal (GI) symptoms alone were detected in 23.6% of the patients; 44.3% of the patients presented with only respiratory symptoms, and 32.1% presented with both respiratory and GI symptoms. Patients with only GI symptoms had less severe disease compared with those who had both GI and respiratory symptoms, who had more severe disease with higher mortality. Overall mortality was 8.6%, with no mortality in the GI symptoms alone group. The highest severity and mortality were in patients with both GI and respiratory symptoms (48.39 and 13.33%, respectively). Conclusions COVID‐19‐related gastrointestinal symptoms are common, and their presence alone carries a better prognosis, but their presence with respiratory symptoms is associated with higher morbidity and mortality.
Methods We designed a cross‐sectional, observational follow‐up for 284 COVID‐19 patients involving healthy patients, smokers, diabetics, and diabetic plus smokers recruited from May 1, 2020 to June 25, 2020. The clinical features, severity, duration, and outcome of the disease were analyzed. Results Of 284 COVID‐19 patients, the median age was 48 years (range, 18–80), and 33.80% were female. Common symptoms included fever (85.56%), shortness of breath (49.65%), cough (45.42%), and headache (40.86%). Patients with more than one comorbidity (diabetes and smoking) presented as severe‐critical cases compared to healthy patients, diabetics, and smokers. Smokers presented with a lower rate of death in comparison to diabetic patients and diabetic + smoking, furthermore, smoking was less risky than diabetes. Although the mortality rate was high in patients with smokers compared to healthy patients (4.22%, the hazard ratio [HR], 1.358; 95% confidence interval [CI], 1.542–1.100; p = .014), it was less than in diabetics (7.04%, HR 1.531, 95% CI: 1.668–1.337, p = .000), and diabetic plus smoker (10.00%, HR, 1.659; 95% CI, 1.763–1.510; p = .000). Conclusion Multiple comorbidities are closely related to the severity of COVID‐19 disease progression and the higher mortality rate. Smokers presented as mild cases compared to diabetic and diabetic + smoking patients, who presented as severe to critical cases. Although a higher death rate in smokers was seen compared with healthy patients, this was smaller when compared to diabetic and diabetic + smoking patients.
Pharmaceutical care is a patient-centered, outcomes oriented practice that requires the pharmacist to work in concert with the patient and the patient’s other healthcare providers to promote health, to prevent disease, and to assess, monitor, initiate, and modify medication use to assure that drug therapy regimens are safe and effective. In addition, the presence of clinical pharmacists has led to a higher quality of patient education and provision of complete detailed information for patients. In developed countries Pharm D has become the professional degree for practice of Pharmacy. The graduates will be enrolled in a pharmacy residency program; admission to the residency programs is available to Pharm D graduates of an accredited College of Pharmacy. The residency is also designed to prepare the residents to become Board Certified Specialists in their field. In many developing countries three new pharmaceutical education programs have currently been established to serve the pharmaceutical care development. Firstly, a six-year curriculum leading to the doctor of pharmacy (Pharm. D) degree as the sole professional degree. Secondly, Pharmacy Residency and Fellowship Training Program have been developed to provide intensive training in pharmaceutical care practice to the pharmacists. Lastly, the continuing pharmaceutical education program (CPE) has been adopted to ensure the competency of all pharmacists to deliver the best knowledge and skills in pharmaceutical sciences in their specialties. In our opinion we lack for most of these programs, even the program of clinical pharmacy in ministry of health is not residency program and it is short and not subspecialized apart from being not recognized by academic institutes and references. In conclusion, pharmacy profession has to change towards the more responsibility on patient care. New training program has to be adopted by medical education institutes to provide clinical pharmacists as a profession and to prepare board certified clinical pharmacists as specialists to cope with the advances in all medical fields. Key words: clinical pharmacy, board certification.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.